116 related articles for article (PubMed ID: 27639574)
1. Comparison of human papillomavirus type 16 replication in tonsil and foreskin epithelia.
Israr M; Biryukov J; Ryndock EJ; Alam S; Meyers C
Virology; 2016 Dec; 499():82-90. PubMed ID: 27639574
[TBL] [Abstract][Full Text] [Related]
2. Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium.
Chatterjee S; Do Kang S; Alam S; Salzberg AC; Milici J; van der Burg SH; Freeman W; Meyers C
J Virol; 2019 Sep; 93(17):. PubMed ID: 31189705
[TBL] [Abstract][Full Text] [Related]
3. SAMHD1 Regulates Human Papillomavirus 16-Induced Cell Proliferation and Viral Replication during Differentiation of Keratinocytes.
James CD; Prabhakar AT; Otoa R; Evans MR; Wang X; Bristol ML; Zhang K; Li R; Morgan IM
mSphere; 2019 Aug; 4(4):. PubMed ID: 31391281
[TBL] [Abstract][Full Text] [Related]
4. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Roden RB; Greenstone HL; Kirnbauer R; Booy FP; Jessie J; Lowy DR; Schiller JT
J Virol; 1996 Sep; 70(9):5875-83. PubMed ID: 8709207
[TBL] [Abstract][Full Text] [Related]
5. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
8. Superinfection Exclusion between Two High-Risk Human Papillomavirus Types during a Coinfection.
Biryukov J; Meyers C
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437958
[TBL] [Abstract][Full Text] [Related]
9. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
[TBL] [Abstract][Full Text] [Related]
10. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
Thönes N; Müller M
Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
[TBL] [Abstract][Full Text] [Related]
11. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
[TBL] [Abstract][Full Text] [Related]
12. Role of L2 cysteines in papillomavirus infection and neutralization.
Gambhira R; Jagu S; Karanam B; Day PM; Roden R
Virol J; 2009 Oct; 6():176. PubMed ID: 19860897
[TBL] [Abstract][Full Text] [Related]
13. Infectious virions produced from a human papillomavirus type 18/16 genomic DNA chimera.
Meyers C; Bromberg-White JL; Zhang J; Kaupas ME; Bryan JT; Lowe RS; Jansen KU
J Virol; 2002 May; 76(10):4723-33. PubMed ID: 11967289
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
[TBL] [Abstract][Full Text] [Related]
15. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
16. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody.
Ishii Y; Tanaka K; Kondo K; Takeuchi T; Mori S; Kanda T
Virology; 2010 Oct; 406(2):181-8. PubMed ID: 20684966
[TBL] [Abstract][Full Text] [Related]
18. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
[TBL] [Abstract][Full Text] [Related]
19. Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
Ning T; Wolfe A; Nie J; Huang W; Chen XS; Wang Y
J Infect Dis; 2017 Oct; 216(7):867-876. PubMed ID: 28968823
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.
Anantharaman D; Gheit T; Waterboer T; Abedi-Ardekani B; Carreira C; McKay-Chopin S; Gaborieau V; Marron M; Lagiou P; Ahrens W; Holcátová I; Merletti F; Kjaerheim K; Talamini R; Simonato L; Castellsague X; Macfarlane TV; Biggs AM; Thakker N; Znaor A; Thomson P; Canova C; Conway DI; Healy CM; Tommasino M; Pawlita M; Brennan P
J Natl Cancer Inst; 2013 Apr; 105(8):536-45. PubMed ID: 23503618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
